University of Rochester Medical Center
Martin Pavelka, PhD
601 Elmwood Avenue
University of Rochester Medical Center
Rochester, NY 14642
https://www.urmc.rochester.edu/research/bsl3-core.aspx
RRID: RRID:SCR_023178
1.) Wlodarchak N, Teachout N, Beczkiewicz J, Procknow R, Schaenzer AJ, Satyshur K, Pavelka M, Zuercher W, Drewry D, Sauer JD, Striker R (2018 Nov 5). In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β-Lactams To Inhibit Mycobacterial Growth. Molecular pharmaceutics, 15(11), 5410-5426. . ID: 30285456.
2.) LoVullo ED, Wright LF, Isabella V, Huntley JF, Pavelka MS Jr (2015 May). Revisiting the Gram-negative lipoprotein paradigm. Journal of bacteriology, 197(10), 1705-15. . ID: 25755189.
3.) Feiler C, Fisher AC, Boock JT, Marrichi MJ, Wright L, Schmidpeter PA, Blankenfeldt W, Pavelka M, DeLisa MP (2013). Directed evolution of Mycobacterium tuberculosis β-lactamase reveals gatekeeper residue that regulates antibiotic resistance and catalytic efficiency. PloS one, 8(9), e73123. . ID: 24023821.
4.) LoVullo ED, Molins-Schneekloth CR, Schweizer HP, Pavelka MS (2009 Apr). Single-copy chromosomal integration systems for Francisella tularensis. Microbiology (Reading, England), 155(), 1152-1163. . ID: 19332817.
5.) LoVullo ED, Sherrill LA, Pavelka MS Jr (2009 Feb). Improved shuttle vectors for Francisella tularensis genetics. FEMS microbiology letters, 291(1), 95-102. . ID: 19067747.
6.) LoVullo ED, Sherrill LA, Perez LL, Pavelka MS (2006 Nov). Genetic tools for highly pathogenic Francisella tularensis subsp. tularensis. Microbiology (Reading, England), 152(), 3425-3435. doi: 10.1099/mic.0.29121-0. ID: 17074911.
The Biosafety Level 3 (BSL3) core facility is available for use by any researcher at the university whose work requires the manipulation of biological agents that may cause serious or potentially lethal disease as a result of exposure by the inhalation route.
